18 December 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its annual report and accounts for the year ended 31 July 2020 has been published on the Company's website and is available to download from: www.c4xdiscovery.com.
Clive Dix talks to Proactive London about taking over as the interim chair of the UK Vaccine Taskforce following the departure of Kate Bingham.
Dix goes on to discuss how this appointment will impact C4X, explaining "if you look at what we've achieved at C4X in the last year, I don't think you'll see a blemish on that productivity".
C4XD's Clive Dix steps up as Interim Chair of UK Vaccine Taskforce
8 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine. The Government will set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.
9 November 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce that at the General Meeting held earlier today in connection with the Company’s Placing at an Issue Price of 14.0 pence, details of which were announced on 21 October 2020, each of the Resolutions were duly passed.
Result of Placing
and Notice of General Meeting
Successfully raises approximately £15.0 million
Advancing the next wave of out-licensing opportunities
21 October 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce the completion of the Placing announced earlier today.